Keros Therapeutics, Inc.
KROS Healthcare Biotechnology
In the quarter to June 2026, revenue fell 99.8%, EPS fell 90.8% and free cash flow grew 32.2%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow KROS
A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Cash and Short Term Investments |
+8 more quarters Free account |
693.47 | 287.42 | 281.50 | 257.61 |
Receivables |
3.49 | 5.82 | 2.65 | 2.25 | |
Total current assets |
719.31 | 315.43 | 290.68 | 266.88 | |
Property, Plant, Equpment (Net) |
4.56 | 4.30 | 3.96 | 3.72 | |
Long-term assets (Other) |
1.45 | 1.45 | 1.45 | 1.45 | |
Total non-current assets |
23.48 | 22.59 | 21.62 | 20.72 | |
Total Assets |
742.78 | 338.02 | 312.29 | 287.60 | |
Accounts Payable |
2.30 | 1.97 | 1.49 | 1.82 | |
Accrued Expenses |
15.17 | 16.04 | 8.86 | 7.74 | |
Current Part of Taxes to Pay |
4.15 | — | — | — | |
Current Revenue (Deferred) |
0.16 | — | — | — | |
Total current liabilities |
24.09 | 20.41 | 12.85 | 12.15 | |
Total non-current liabilities |
15.11 | 14.48 | 13.81 | 13.13 | |
Total liabilities |
39.20 | 34.89 | 26.66 | 25.28 | |
Additional Paid In Capital |
1,161.88 | 1,169.45 | 1,175.66 | 1,181.06 | |
Common Stock (Net) |
0.00 | 0.00 | 0.00 | 0.00 | |
Retained Earnings |
(458.30) | (481.76) | (505.47) | (534.18) | |
Treasury Stock |
— | 384.56 | 384.56 | 384.56 | |
Common Equity (Total) |
703.58 | 303.13 | 285.63 | 262.32 | |
Shareholders Equity (Total) |
703.58 | 303.13 | 285.63 | 262.32 | |
Shareholders Equity and Liabilities (Total) |
742.78 | 338.02 | 312.29 | 287.60 | |
Shares (Common) |
40.63 | 19.54 | 19.73 | 19.83 | |
Shareholders Equity (Tangible) |
703.58 | 303.13 | 285.63 | 262.32 | |
Net Debt |
(693.47) | (287.41) | (281.50) | (257.61) |